VivoSeq
Other

Chordoma

24

Pipeline Programs

6

Active Trials

12

Companies Involved

Chordoma is an emerging landscape with 24 programs across 12 companies. The most active players are Eagle Vision Pharmaceutical Corp., Azurity Pharmaceuticals, Novartis.

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

90/100

Attrition Rate

5/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

19programs
Small molecule1053%
Monoclonal antibody526%
Protein / enzyme316%
Vaccine15%

Modality classified for 100% of 24 pipeline programs.

Trial Status

20

clinical trials

Completed9 · 45%
Unknown status4 · 20%
Recruiting4 · 20%
Active, not recruiting2 · 10%
Withdrawn1 · 5%

Trial Activity

20 trials

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Completed·NNantCell, Inc.·Phase 2·NCT02383498·24 enrolled
BN Brachyury and Radiation in Chordoma
Completed··Phase 2·NCT03595228·29 enrolled
Efficacy and Safety of Imatinib in Chordoma
Completed·Novartis logoNovartis·Phase 2·NCT00150072·55 enrolled
Pemetrexed for the Treatment of Chordoma
Completed·SSaint John's Cancer Institute·Phase 1·NCT03955042·15 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)